SIN3B and neoplasm: conducted in vivo epigenetic CRISPR screens using mouse tumor models to systematically identify chromatin regulators that influence tumor immunity and the efficacy of ICB therapies.[3] Notably, Sin3B emerged as one of the potential candidate genes in this screening.